Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-859 After Single Ascending Doses in Healthy Adult Subjects

NCT07736638 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07736638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07736638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-859 After Single Ascending Doses in Healthy Adult Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
July 28, 2026
Completion date
February 28, 2027
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer